Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for UXT drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | UXT Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Ideal for PPI screening. |
View UXT Products |
| Gene Delivery | UXT Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and functional rescue assays. |
View UXT Products |
| Benchmark Ab | Anti-UXT Recombinant Antibody Recombinant positive control for Western Blot, IP, and IHC validation. |
View UXT Products |
| Validator | UXT siRNA Set Target-specific knockdown verification in tumor cell lines. |
View UXT Products |
| Related Target A | Androgen Receptor (AR) UXT acts as a critical transcriptional co-activator for AR in prostate cancer. |
View AR Products |
| Related Target B | EZH2 Epigenetic regulator interacting with UXT to modulate oncogenic gene expression. |
View EZH2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Protein-Protein Interaction (PPI) screening (e.g., UXT-AR binding) | High-purity, natively folded recombinant proteins with theoretical MW verification. |
| Intracellular localization and function validation | Lentivirus-mediated stable expression showing robust transgene performance in cell-based assays. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies and positive controls included. |
| False Positives | Validated siRNA pool included for target-specific knockdown verification. |
Live UXT R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for UXT therapeutics is intensifying, with major players shifting focus from traditional systemic chemotherapy to targeted transcriptional modulators and protein-protein interaction (PPI) disruptors. As first-generation therapies targeting the androgen receptor (AR) axis face resistance, the next wave of R&D is targeting nuclear co-activators like UXT to bypass classic mutation-driven drug resistance.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Inhibitor) | Academic Institutes, Biotech Startups | Castration-Resistant Prostate Cancer (CRPC) | In vitro binding assays (Need high-purity recombinant UXT protein) |
| PROTAC / Degrader | Oncology-focused Biotechs | Breast Cancer, Solid Tumors | Degradation kinetics (Need stable cell line via Lentivirus) |
| RNA Therapeutics (siRNA/ASO) | RNAi Specialists | Metastatic Cancers | In vitro knockdown validation (Need verified siRNA sets) |